NewswireToday - /newswire/ -
Greenville, NC, United States, 2014/06/26 - New spray dryer allows company to render powder from solution, and to modify particle sizes - MetricsInc.com.
Metrics, Inc. has expanded its already robust options for enhancing drug bioavailability thanks to the recent acquisition of a BÜCHI B-290 Mini Spray Dryer.
The dryer’s core capability is rendering powder from a solution, said Brad Gold, Ph.D., vice president of pharmaceutical development. In addition, in single-unit operation, the dryer is useful for modifying particle size, agglomerating nanoparticles, drying suspensions and microencapsulation.
“Because spray drying, especially with organic solvents, is a leading technique for enhancing drug availability, this acquisition allows Metrics to offer even more drug-delivery options to our clients,” Gold said. “It also reflects Metrics’ ongoing investment in facilities and equipment to preserve our standing as the outsourcing partner of choice for contract pharmaceutical services.”
Metrics recently opened a $1.6-million, 4,524-square-foot facility specifically designed for the pre-clinical development of early formulation prototypes and related analytical methods. Working in the segregated and dedicated pre-clinical laboratory, Metrics formulators and chemists have significant autonomy to conduct development activities quickly.
The BÜCHI B-290 Mini Spray Dryer quickly and gently spray dries liquid end products to powder form, Gold said, and has the ability to handle solvents safely by providing an inert atmosphere for processing.
Metrics, Inc. (metricsinc.com) is a full-service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.
Our company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial scale manufacturing.
Our technical capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence, for which we offer an impressive proprietary portfolio of advanced delivery methods.
Located in Greenville, N.C., Metrics Inc. proudly operates as a subsidiary of Mayne Pharma Group Limited. Learn more online.